

Recurrent Anaplastic Astrocytoma					
PI	CRC	Protocol #/Title	Mechanism	Primary In/Ex Criteria	Status
Bota	Jennifer Scott	UCI 16-22: A Phase 3, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemo	Enzyme ornithine decarboxylase (ODC) inhibitor	First AA tumor progression or recurrence ≤ 3 months prior to randomization based on MRI criteria for tumor progression. Completion of EBRT ≥ 6 months prior to randomization.	Open to Accrual
Newly Diagnosed Anaplastic Glioma\Low grade Glioma					
Kong	Ricardo Avalos	N0577 Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma	1p/19q codeleted oligodendroglioma patients.	1p/19q Co-deletion and IDH Mutation Newly diagnosed and ≤ 3 months from surgical diagnosis Histological evidence of WHO grade III anaplastic glioma or WHO	Open to Accrual
Newly Diagnosed Glioblastoma					
PI	CRC	Protocol #/Title	Mechanism	Primary In/Ex Criteria	Status
Bota	Julie Nguyen	UCI 17-115: Phase II trial of AV-GBM-1 (autologous dendritic cells loaded with autologous tumor associated antigens) as an adjunctive therapy following primary surgery plus concurrent chemoradiation in patients with newly diagnosed glioblastoma	Autologous dendritic cells loaded with autologous tumor associated antigens and admixed with adjuvant GM-CSF prior to injection	Newly diagnosed GBM patients scheduled for surgical resection at UC Irvine	Open to Accrual
Bota	Jennifer Scott	UCI 18-108: Phase III Trial of Marizomib in Combination With Standard Temozolomide-Based Radiochemotherapy Versus Standard Temozolomide-Based Radiochemotherapy Alone in Patients With Newly Diagnosed Glioblastoma	Proteasome inhibitor	Newly diagnosed Prior treatment for low grade excluded IDH mutations excluded	Open to Accrual
Recurrent Glioblastoma					
PI	CRC	Protocol #/Title	Mechanism	Primary In/Ex Criteria	Status
Kong	Jennifer Scott	UCI 17-35: A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion Combination with Bevacizumab (Bev) versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy	Synthetic peptide vaccine	At least one HLA positive -First recurrence of GBM only Avastin Naive Measurable disease	Open to Accrual
Bota	Mehir Tharani	UCI 13-14: A Randomized, Double-Blinded, Placebo-Controlled Phase II Study of (ERC1671/ GM-CSF / Cyclophosphamide) + Bevacizumab versus (Placebo Injection / Placebo pill) + Bevacizumab in the Treatment of Recurrent/Progressive, Bevacizumab Naïve Glioblast	ERC1671:Course of vaccines containing irradiated whole and lysed primary tumor cells from allogeneic and autologous GBM patients	First/Second recurrence of GBM Avastin Naive	Open to Accrual

Manisha Dandekar 456-6221
 Jennifer Scott 509-2370
 Ricardo Avalos 509-2495
 Mehir Tharani 509-2643
 Julie Nguyen 456-5956
 Siranush Herculian 509-2759

Newly Diagnosed Meningioma					
PI	CRC	Protocol #/Title	Mechanism	Primary In/Ex Criteria	Status
Kong	Mehir Tharani	NRG BN003: Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma	Radiation Therapy	Newly diagnosed unifocal intracranial meningioma Gross totally resected Central Pathology Review for confirmation of histology	Open to Accrual
Recurrent Meningioma					
PI	CRC	Protocol #/Title	Mechanism	Primary In/Ex Criteria	Status
Bota	Mehir Tharani	A071401: Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2 Mutations	SMO competitive antagonist, FAK inhibitor	Central pathology review for SMO/Ptch1/NF2 mutation Progressive or residual disease in Meningioma Measurable disease per RANO criteria	Temporarily suspended
Craniopharyngiomas					
PI	CRC	Protocol #/Title	Mechanism	Primary In/Ex Criteria	Status
Bota	Mehir Tharani	Alliance A071601: Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas	BRAF/MEK inhibitors	Central pathology review with positive BRAF V600E mutation by IHC Measurable disease No prior treatment with BRAF or MEK inhibitors	Open to Accrual
CNS Metastases					
PI	CRC	Protocol #/Title	Mechanism	Primary In/Ex Criteria	Status
Rare Cancers					
PI	CRC	Protocol #/Title	Mechanism	Primary In/Ex Criteria	Status
Bota	Manisha Dandekar	ECOG EAY131: Molecular Analysis for Therapy Choice (MATCH)	Treatment based on mutations	Positive for specific mutations	Open to Accrual
Bota	Mehir Tharani	SWOG S1609: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors	Immunotherapy	Recurrent disease - Rare cancer	Open to Accrual

Supportive Care/Diagnostic					
PI	CRC	Protocol #/Title	Mechanism	Primary In/Ex Criteria	Status
Chow	Jennifer Scott	ECOG EAF151: Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma	Imaging trial	Recurrent glioblastoma or gliosarcoma Avastin Naïve with plan to administer Avastin either as single therapy or in conjunction with other chemotherapeutic regimens	Open to Accrual
Bota	Jennifer Scott	UCI 18-83 Pilot Study of Mirtazapine for the Dual Treatment of Depression and Temozolomide-Induced Nausea and Vomiting (CINV) in Newly-Diagnosed High-Grade Glioma Patients on Temozolomide Therapy	Antidepressant	Histologically confirmed diagnosis of glioma -No prior treatment with temozolomide TMZ -Patient will receive temozolomide TMZ therapy as part of their standard treatment.	Open to Accrual